Key Insights

Highlights

Treatment Research

1 treatments under study, led by Mannanconjugated Allergoid Polymerized Betula Pendula Parenteral Vaccine

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
SYF9a96a569b8784d3a888941f2f924f4f7Phase 3Unknown

A prospective, randomized, double-blind placebo-controlled multicentre study with mannan-conjugated birch pollen allergoids administered subcutaneously to adolescent and adult patients with birch pollen-induced allergic rhinitis or rhinoconjunctivitis.

Showing all 1 trials

Research Network

Common Treatments

  • Mannanconjugated Allergoid Polymerized Betula Pendula Parenteral Vaccine1

Active Sponsors

  • Inmunotek S.L.1
  • CCDRD Cooperative Clinical Drug Research and Development AG1
  • ClinCompetence Cologne GmbH1

Activity Timeline